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t>()'RIGINAL ARTICLE

NON-CARDIAC SURGERY IN PATIENTS WITH PROSTHETIC
IIEART VALVES: A 12 YEARS EXPERIENCE
:'~aja parvez Akhtar,

Abdul Rehman Abid,' Hasnain Zalar, Syed Javed Raza Gardezi," Abdul Waheed and Jawad Sajid Khan

ABSTRACT

I

Objective: To study patients with mechanical heart valves undergoing non-cardiac surgery and their anticoagulation
management during these procedures.
study Design: It was a cohort study.
Place and Duration of Study: The study was conducted at the Department of Cardiac Surgery, Punjab Institute of
. cardiology, Lahore and Department of Surgery, Services Institute of Medical Sciences, Lahore, from September 1994 to
June 2006.
patients and Methods: Patients with mechanical heart valves undergoing non-cardiac surgical operation during this
period, were included. Their anticoagulation was monitored and anticoagulation related complications were recorded.
Results: In this study, 507 consecutive patients with a mechanical heart valve replacement were followed-up. Forty two
(8.28%) patients underwent non-cardiac surgical operations of which 24 (57.1 %) were for abdominal and non-abdominal
surgeries, 5 (20.8%) were emergency and 19 (79.2%) were planned. There were 18 (42.9%) caesarean sections for
· pregnancies. Among the 24 procedures, there were 7(29.1 %) laparotomies, 7(29.1%) hernia repairs, 2 (8.3%)
cholecystectomies, 2 (8.3%) hysterectomies, 1(4.1 %) craniotomy, 1 (4.1 %) spinal surgery for neuroblastoma, 1(4.1 %) ankle
fracture and 1(4.1%) carbuncle. No untoward valve or anticoagulation related complication was seen during this period.
Conclusion: Patients with mechanical valve prosthesis on life-long anticoagulation, if managed properly, can undergo any
type of non-cardiac surgical operation with minimal risk.
KEY WORDS: Rheumatic heart disease.

Mechanical heart valves. Non-cardiac surgery.

Anticoagulation.

INTRODUCTION
·Rheumatic heart disease (RHO) is seen in endemic
proportions in Pakistan with a prevalence of 5.7/1000.1 A
large number of these patients are young and present late.!
Due to recurrent attacks of rheumatic fever (RF), their valves
are severely diseased.' In majority of patients, these valves
are not suitable for percutaneous transvenous mitral
commissurotomy (PTMC) or surgical repair,' and this leaves
the only option of valve replacement.' Bioprosthetic or tissue
valves in young patients with rheumatic fever are prone to
early degeneration and valve failure leading to a revision
.operation.' Hence, patients are left with mechanical valve
prosthesis, for which life-long anticoagulation with Warfarin
is required.
When patients with mechanical valves require surgery, their
perioperative management of Warfarin therapy poses a major
problem.• These patients undergoing non-cardiac surgery
have a thromboembolic (TE) event rate of 0-2% for aortic valve
replacement and 11-20% for mitral valve replacement.S-7
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Kearon et al. have reported a reduction in the incidence of TE
events at the cost of increased major postoperative bleeds in
patients receiving intravenous heparin.B Risk of TE is from
1-22%.9-11

In order to assess TE and risk of haemorrhage, this study was
conducted to evaluate the effect of our anticoagulation
strategy on postoperative outcome of patients with
mechanical heart valves undergoing non-cardiac surgery.

pATIENTS AND METHODS
All the patients who underwent valve replacement with a
mechanical prosthesis for rheumatic heart disease from
September 1994 till June 2006 were included in this cohort

study. They were followed-up regularly in the author's
outpatient clinic. During follow-up period, their international
normalized rati.o (INR) and Warfarin dose was monitored and
yearly echocardiography was done. Anticoagulation related
events were also recorded .
Patients with a mechanical heart valve, requiring non-cardiac
surgical operation for acute or elective procedufe, were

studied with emphasis to their postoperative outcome.
Patients were broadly classified as having emergency or
planned surgery. Patients undergoing emergency surgery
were admitted under the care of a general surgeon and INR
was monitored, if it was >2, they were given fresh frozen
plasma '(FFP) along with Vitamin K. Once the INR was <1.5,
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surgery was pertormed. 1-'ostoperatlvely, w1thm 6-lL hours,
patients were restarted on intravenous unfractionated heparin
(Heparin Leo Pharma UK, 1 millilitre~5000 IU)) [I/V UFH]
and activated partial thromboplastin time (APIT) was
monitored 6 hourly with a target of keeping it 2-3 times the
control. Oral anticoagulation with Warfarin was restarted
24 hours following surgery and I/V UFH was continued till
INR was >2.0. Prior to discharge, an echocardiography was
performed to rule out any clot formation around the
prosthetic valve or LA. Infective endocarditic prevention
with intravenous antibiotics was given 6 hours preoperatively and for 48 hours postoperatively followed by oral
antibiotics for 7 days.
Patients undergoing planned surgery were admitted 36 hours
pre-operatively and Warfarin was discontinued and their INR
monitored. Once this was below 2, I/V UFH was commenced
keeping the APIT 2 times the control and when the INR was
<1.5, the planned procedure was performed. I/V UFH was
discontinued 6 hours prior to shifting to the operation room.
Infective endocarditic prevention was similar to acute group.
Postoperatively anticoagulation was managed as in the
emergency group. The same protocol was used in pregnant
patients the only difference being that they were switched to
I/V UFH in the last 2 weeks of pregnancy and Warfarin was
discontinued.
Once the patient was ambulant, an echocardiography was
performed to assess the prosthesis for function and formation
of clot or thrombus. A second echocardiography was done at
8 weeks. All the patients were followed up till June 2006.
The data was analyzed by using SPSS 14.0 (Statistical Package
for Social Sciences Version 14.0) for Windows (SPSS Inc.
Chicago, 11, USA). Categorical variables were expressed as
percentages while continuous variables were expressed as
mean ± standard deviation. Events were defined as
thromboembolic and hemorrhagic complications.

RESULTS
During the study period, a total of 507 patients who had
undergone mechanical heart valve replacement were followed
up. The mean age of the study population was 29.5±11.32
years. There were 292 (57.6%) males and 215 (42.4%) females.
Two hundred and sixty-eight (52.8%) patients underwent
prosthetic heart valve replacement for mitral valve disease
followed by combined mitral and aortic valve disease 96
(18.9%). Ball and cage valve was most frequently implanted
345 (68%) followed by bileaflet and single disc valves. Table I.
All patients were followed up for a total of 2008.5 patient
years, mean 3.96 ± 3.3 years, median 3.42 years with a range of
0.16 - 12.08 years. All patients had undergone surgery by a
single surgeon at the Cardiac Surgery Departinent, Punjab
Institute of Cardiology, Lahore. In-hospital mortality was
25 (4.9%) and there were 62 (12.2%) late deaths. At the end of
12 years, 352 (69.4%) patients were alive and had regular
follow-up. Seven (1.4%) patients never came for follow-up and
we were unable to obtain complete follow-up data on 61(12%)
patients. Forty-two patients had non-cardiac surgery and had
follow-up during this period. Of these, 24(57.1 %) patients had
a variety of surgical procedures, among these 5(20.8%)
underwent emergency and 19 (79.2%) had planned surgery.
There were 18(42.9%) caesarean sections for pregnancies.
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tive patients unctergomg acute; emergency opera .
comprised of 4 females and a male. All female pat; lions
entshct
mitra 1 va lve replacements. Three females und
a
laparotomies, 2 for ectopic pregnancies and 1 for s:r~ent
oophorectomy. One female underwent craniotomy for Pingo
intracerebral bleed. qt>e male patient having aortic acute
replacement and diabetes mellitus underwent Valve
operation for carbuncle. Nineteen patients had pl acute
anne·
operations Table II.
a
Eighteen (42.9%) patients had caesarean sections and had .
1
births with no postoperative thromboembolic complicat· IVe
Ions.
There was no episode of thromboembolism (TE) or
operative bleeding in this series. Two patients ha/ost.
·
· h mtracrama
·
· 1 bl eed and one W"th
one
transfu swn
eac h, one Wit
1
spinal neuroblastoma. All patients in this study group were
the high risk group forTE due to large LA, AF or having a b;~
and cage valve.
At the end of study period, 2 (4.7%) out of 42 patients died
one of arrhythmia and the other of renal failure. Th'
remaining 40 patients had 1300 visits at the author':
outpatient clinic. The mean INR of these patients was
2.6 ± 0.47, maintained on a mean warfarin dose of 5.14 ± 1.3.

DISCUSSION
Cardiac surgery services are improving in Pakistan with an
increase in number of centres and open heart surgeries
performed regularly. More patients with mechanical valve
prosthesis implanted for rheumatic valve disease will be seen
over the next few years. This is a relatively young population
on life-long anticoagulation and will require a non-cardiac
surgical intervention at some stage. In the West, apart from
anticoagulation for mechanical valve prosthesis, a large
number of patients require anticoagulation for non-valvular
atrial fibrillation and venous thromboembolism.4~
The risk of withholding warfarin in patients with mechanical
valve prosthesis and AF for thromboembolism is high. It has
been reported to increase to 3.7 fold.4 Whereas Kearon et a/.8
Table 1: Epidemiological characteristics of the study population.
Total n,so?
29.5 ±11.32

Characteristics
Age mean years
Male
Female
Diagnosis

292 (57.6%)
215 (42.4%)
268 (52.8%)

Isolated mitral valve disease
Isolated aortic valve disease
Aortic and mitral valve disease
Mitral and tricuspid valve disease

76 (15%)
96 (18.9%)
45 (8.9%)

Aortic mitral and tricuspid valve disease
Aortic valve with IHD
Mitral valve with tHO
Mitral and aortic valve disease with JHD
Mitral and tricuspid valve disease with IHO
Mitral valve with other associated lesions like ASD, PFO
Prosthesis implanted
Ball and cage
Single disc
Bileaflet

4 (0.8%)
4(0.8%)
2(0.4%)
2 (0.4%)
1 (0.2%)
9 (18%)
345 (68%)_
36 (7.1%J..

126(24.9~

IHD= Ischemic Heart Disease; ASD= Atrial Septal Defect; PFO= Patent Foramen Qvale
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Pi~. Characteristics of patients undergoing non-cardiac surgery.
sex

. _S:No.

Valve
replaced

- ·
·. ,~
.I
:~

Non-cardiac
surgical
procedure

Acute/
Adverse
planned outcome

F

MVR B&C

Laparotomy

P

Nil

F

MVR B&C

Laparotomy (SO)

P

Nil

F

MVR B&C

Lumpectomy
breast

p

Nil

+ Hysterectomy

•; ·2 '.:.--- 40

3

;--~-3~s,___cF_ ___:M::V~R~B:c_&'OC-___:L::,:a:cp::ar_::o:::lo:::m:!.y.:"(E::P-")--':A:___NC"ic_l_
·:_·;--- 35

F

MVR B&C

Cholecystectomy

P

Nil

;;·....--

48

M

MVR B&C

Hernia

P

Nil

24

M

AVR B&C

Hernia

P

Nil

.~

7

•/s!·
____:20:4'--_:F_ _M"':':VR::-.:B_::&: :.C_ _,L::a:c:P::ar:::_o:::lo::m"-y-'(E:;P_,)_-':A:-------:'Ni::_l_
32

M

MVR BV

Hernia

P

_:: 10

22

M

MVR B&C

Hernia

P

Nil

Nil

, :. jj

38

F

MVR+TV S/0

Hysterectomy

P

Nil

_
12

21

F

MVR B&C

Laparotomy (SO)

A

Nil

13

37

F

MVR B&C

Hysterectomy

P

Nil

14

48

M

MVR+AVR

Fracture ankle

P

Nil

Carbuncle

A
p

Nil

Laparotomy {SO)
Neuroblastoma
spine

p

Nil

Hernia

p

Nll

Mastectomy

p

Nil

Craniotomy

A
p

Nil
Nil

15

40

M

16

45

F

BV
AVR BV
MVRBV

17

20

M

MVR+AVR

18

18

M

BV
AVA B&C

19

30

F

MVR+AVR

F
F

20
21
22
23
24

Nil

26

M

B&C
MVR BV
MVR B&C
MVR B&C

Hernia

p

21

M

MVR+AVR BV Hernia

p

Nil

50

F

MVR+AVR BV LAP CHOLE

p

Nil

16

33

C/S + TL

Nil

AVA=Aortic valve replacemenl: MVR.=.Milral valve replacement; B&C=Ball and Cage valve;
BV..Bileafiet valve: SID,. Single disc valve;
FoFemale:
M=Male;
so..Salplngo oophorectomy;
.EP.:Ectopic pregnancy, CIS +TL., Caesarean &ec1kln + 1uballigatkm; Lap CHOLE:Laparoscopic
c001eetec1omy.

have shown that of 10,000 patients with mechanical valves
who are given intravenous heparin, 3 thromboembolic
episodes are prevented at the risk of 300 major postoperative
bleeds.'
Gohlke~Barwolf et ars

have shown that the risk of TE varies
from 0~2% in AVR and 11 - 20 % in MVR.S Prendergast eta/.
have shown that the risk of TE for patients with prosthetic
valve without anticoagulation is from 8-22% per annum and
0.02-0.06% per day.' Withholding anticoagulation to a sub~
therapeutic level has a theoretical risk of TE of 0.08~0.36%.9
This may be even higher depending upon rhythm, type of
prosthesis, LA size, LV function and previous history of TE.'
The occlusion of prosthetic valve has been reported to occur
in 1~13% of cases.1o There is an approximately 4~8 per 100
patient~year rate of major thromboembolism in patients not
receiving long~tenn anticoagulation therapy.n Factors which
predispose to an increased risk of thromboembolism include
number of valves placed, type of valve implanted (greater in
ball and cage variety), mitral valve replacement, atrial
fibrillation, left atrial enlargement, LV dysfunction, dotting
disorder and prior embolic event.12
ln this study of 507 patients, 42 underwent non~cardiac
surgical operations; 5 were emergency; 19 were planned
operations and 18 were caesarean sections. This was a
challenge as it involved a multidisciplinary approach in
collaboration with another hospital smgical team. Larson
JCPSP 2007, Vol. 17 (10): 583-586

et a!.13 and Douketis et al.l4 have described in their articles that

there is no consensus regarding the management of
perioperative anticoagulation in these patients.13,14 This is
largely due to lack of clinical trials investigating different
strategies.!' The most commonly used strategy is to admit the
patient 3-4 days pre~opera!~vely, discontinue their Warfarin
monitor INR once below therapeutic range start IV UFH.13
This is stopped 3 hours before surgery, 1/V UFH is restarted
6-12 hours after surgery along with oral warfarin therapy. The
incidence for postoperative major bleeding has been reported
as 10.9% with low molecular weight heparin (LWMH), 12.1%
with UFH.13 There was no episode of thromboembolism,
valve thrombosis or haemorrhage in this series. Heparin is
continued till INR is in therapeutic range.
It has been reported by some that the risk of TE is exaggerated
and IV heparin should only be used in patients with previous
history of TE. A less aggressive approach is temporary
discontinuation of warfarin and substituting it with
subcutaneous UFH or LMWH. Authors do not agree with this
as patients included in this study are at high risk of TE and
anticoagulation was sub-therapeutic due to the reasons
mentioned above.

Ansell et aJ.l5 in their article have recommended that patients
with a high risk of TE should withhold warfarin 4 days prior
to surgery and allow the INR to fall below the therapeutic
range and commence the patients on full dose heparin or
LMWH and to stop this 3-6 hours before the surgery. In this
studym the INR levels was maintained on the lower
therapeutic range (2~2.5) thus the admission 24~36 hours pre~
operative is sufficient and in planned surgeries their warfarin
dose was reduced a week before surgery. On admission, their
INR was around 1.8~2.2; I/V UFH was started and warfarin
was omitted, once INR was <1.5, they underwent surgery.
Reduced pre-operative admission time was thus seen.

Authors agree with Gohlke~Barwolf et af.S that for major
surgery, it is required to lower the INR to <1.5 and 1/V UFH
commenced once INR was <2 and APTI should be maintained
at 1.5 ~ 2 times the control. Heparin is held 3-6 hours prior to
surgery and to restart it 6~12 hours postoperation with an aim
to keep APTI 2 times normal. Warfarin is restarted 24 hours
postoperatively or when patients can start oral intake. With
this regime in this cohort, no postoperative hemorrhagic or
thromboembolic complication was seen. Goldman et aJ.16 have
reported a high risk of bleeding postoperatively and have
stressed on lowering the INR to avoid hemorrhagic
complications.l6
In case of emergency surgery, the affect of warfarin needs to be
neutralized by FFP, the dose of which depends upon the
individual and this is titrated till INR was <1.5. In addition to
this, vitamin K may also be given intravenously in small doses
as large doses may lead to resistance to warfarin once, it is
restarted following surgery.s
In patients who were pregnant and undergoing caesarean
section, they were admitted and their warfarin was
discontinued two weeks prior to the due date and they were
commenced on 1/V UFH and APTI was kept at 2~3 time the
normal. The recommendations of European Society of
Cardiology" and American College of Cerdiology" for
anticoagulation during pregnancy in patients with prosthetic
valves to be opted after discussion with the patient and
spouse.
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6.

Carrel TP, Klingemann W, Mohacsi PJ. Perioperative b! .
thromboembolic risk during non-cardiac surgery in p~~drng ana
mechanical prosthetic heart valves: an institutional revi~~ts l'lith
Valve Dis 1999; 8: 392-8.
·1 Hean

7.

Dunn AS, Turpie AG. Perioperative management of
.
receiving oral anticoagulants: a systematic review. Arch !atrents
1
2003;163: 901-8.
""Mel

8.

Kearon C, Hirsh J. Management of anticoagulation before
after elective surgery. N Eng/] Med 1997; 336: 1506-11.
ana

Warfarin recommendations by Amercian Heart Association
and British Committee for Standards in Haematology have
also emphasized optimization of anticoagulation therapy in
patients of mechanical heart valves undergoing non-cardiac
surgery.I9-21

9.

Prendergast B. Anticoagulation for patients with prosthetic h
valves during non-cardiac surgery. E-Journal of Cardioleart
Practice [serial on the internet]. 2004 Mar [cited 2007 Oct 4 ~gy
2
[about 2 p.] Available from: http:// www.escardio.org/ knowlect' ·
cardiology- practice/e journal -val 2/ val 2 no. 26-htm.
gel

Authors agree with the recommendations given by Sridhar
"aJ.4 and broadly follow that protocol. The only modification
recommended is in planned surgery, the dose of warfarin can
be tapered one week prior to the planned date of admission as
descussed earlier.

10. Sharma N, Grover A, Radotra BD. Prosthetic cardiac valve
replacement: management problems. Asian Cardiovasc 7borac Ann
1998; 6:179-82.

CoNcLUsiON

12. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP
Freed MD, et a!. ACCI AHA 2006 Practice guidelines for th;
management of patients with valvular heart disease: executive
summary.] Am Coli Cardiol 2006; 48: 598-675.

Oh et af.l8 have reported a survey conducted by Korean
physicians regarding 4 different scenarios and a questionnaire
was sent "With four treatment options in each scenario. Their
answers showed a substantial variability. A similar survey by
the Canadian Society of Internal Medicine was carried out,14
which showed that the most frequent regime was pre and
post-operative 1/V UFH therapy. Intensity of anticoagulation
was influenced by the risk of TE and not haemorrhage in both
the surveys.

Patients with mechanical valve prosthesis, on life-long
anticoagulation, if managed properly, can undergo any type of
non-cardiac surgical operation with minimal risk.
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